KURE holdings
All 63 positions of KraneShares MSCI All China Health Care Index ETF.
Positions
63
Top 10 weight
53.9%
Effective holdings
24.5
1 / sum of squared weights
In stocks
99.7%
In bonds
0.0%
Outside the US
98.4%
Asset mix
Sectors
1% of stocks classifiedCountries
Holdings
| # | Holding | Type | Weight | Value | Shares / par | Country |
|---|---|---|---|---|---|---|
| 1 | BEIGFBEONE MEDICINES LTD | Equity | 8.84% | $6.3M | 289,918 | HK |
| 2 | INNOVENT BIOLOGICS, INC. | Equity | 8.80% | $6.3M | 617,500 | HK |
| 3 | WUXI BIOLOGICS (CAYMAN) INC. | Equity | 7.51% | $5.4M | 1,212,635 | HK |
| 4 | WuXi AppTec Co., Ltd. | Equity | 5.79% | $4.1M | 224,720 | CN |
| 5 | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | Equity | 4.59% | $3.3M | 426,408 | CN |
| 6 | Shenzhen Mindray Bio-Medical Electronics Co Ltd | Equity | 4.27% | $3.0M | 152,155 | CN |
| 7 | Akeso Inc | Equity | 3.72% | $2.6M | 236,000 | HK |
| 8 | CSPC PHARMACEUTICAL GROUP LIMITED | Equity | 3.68% | $2.6M | 2,948,889 | HK |
| 9 | Invesco Government & Agency Portfolio | Cash | 3.55% | $2.5M | 2,526,804 | US |
| 10 | SINO BIOPHARMACEUTICAL LIMITED | Equity | 3.39% | $2.4M | 4,287,750 | HK |
| 11 | WuXi AppTec Co., Ltd. | Equity | 3.35% | $2.4M | 121,784 | HK |
| 12 | HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED | Equity | 2.85% | $2.0M | 538,000 | HK |
| 13 | 3SBio Inc. | Equity | 2.49% | $1.8M | 822,500 | HK |
| 14 | YUNNAN BAIYAO GROUP CO., LTD | Equity | 2.30% | $1.6M | 235,223 | CN |
| 15 | Shanghai United Imaging Healthcare Co., Ltd. | Equity | 2.27% | $1.6M | 108,508 | CN |
| 16 | Aier Eye Hospital Group Co., Ltd. | Equity | 2.10% | $1.5M | 1,227,963 | CN |
| 17 | Sichuan Biokin Pharmaceutical Co Ltd | Equity | 1.97% | $1.4M | 32,322 | CN |
| 18 | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Equity | 1.85% | $1.3M | 23,700 | HK |
| 19 | ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD. | Equity | 1.73% | $1.2M | 76,734 | CN |
| 20 | SINOPHARM GROUP CO. LTD. | Equity | 1.67% | $1.2M | 586,800 | HK |
| 21 | Sichuan Kelun Pharmaceutical Co., Ltd. | Equity | 1.55% | $1.1M | 194,015 | CN |
| 22 | Haisco Pharmaceutical Group Co., Ltd. | Equity | 1.53% | $1.1M | 111,200 | CN |
| 23 | HUADONG MEDICINE CO., LTD | Equity | 1.36% | $969K | 233,941 | CN |
| 24 | WuXi XDC Cayman Inc | Equity | 1.35% | $964K | 132,500 | HK |
| 25 | Shanghai Allist Pharmaceuticals Co Ltd | Equity | 1.34% | $954K | 59,328 | CN |
| 26 | LEGNLegend Biotech Corporation American Depositary Shares | Equity | 1.28% | $909K | 31,488 | US |
| 27 | RemeGen Co Ltd | Equity | 1.26% | $896K | 46,717 | CN |
| 28 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | Equity | 1.24% | $882K | 266,529 | CN |
| 29 | Pharmaron Beijing Co., Ltd. | Equity | 1.15% | $818K | 191,875 | CN |
| 30 | Shanghai Pharmaceuticals Holding Co., Ltd. | Equity | 1.13% | $807K | 355,812 | CN |
| 31 | Genscript Biotech Corp | Equity | 1.11% | $792K | 508,000 | HK |
| 32 | RemeGen Co Ltd | Equity | 1.05% | $748K | 79,000 | HK |
| 33 | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. | Equity | 1.03% | $731K | 220,711 | CN |
| 34 | XtalPi Holdings Limited | Equity | 1.00% | $709K | 727,000 | HK |
| 35 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Equity | 0.94% | $668K | 142,265 | CN |
| 36 | Shenzhen New Industries Biomedical Engineering Co Ltd | Equity | 0.90% | $643K | 103,900 | CN |
| 37 | BEIJING TONG REN TANG CO., LTD | Equity | 0.86% | $614K | 180,490 | CN |
| 38 | Shanghai RAAS Blood Products Co., Ltd. | Equity | 0.79% | $560K | 876,134 | CN |
| 39 | Chongqing Zhifei Biological Products Co., Ltd. | Equity | 0.76% | $543K | 315,472 | CN |
| 40 | CSPC Innovation Pharmaceutical Co Ltd | Equity | 0.74% | $529K | 131,757 | CN |
| 41 | CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. | Equity | 0.74% | $527K | 53,708 | CN |
| 42 | Imeik Technology Development Co Ltd | Equity | 0.72% | $512K | 39,840 | CN |
| 43 | APT Medical Inc | Equity | 0.70% | $497K | 18,599 | CN |
| 44 | Beijing Wantai Biological Pharmacy Enterprise Co Ltd | Equity | 0.67% | $479K | 120,442 | CN |
| 45 | Hebei Changshan Biochemical Pharmaceutical Co Ltd | Equity | 0.56% | $402K | 116,500 | CN |
| 46 | Hangzhou Tigermed Consulting Co., Ltd | Equity | 0.46% | $324K | 45,850 | CN |
| 47 | ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD. | Equity | 0.08% | $55K | 3,400 | CN |
| 48 | Sichuan Kelun Pharmaceutical Co., Ltd. | Equity | 0.07% | $49K | 8,600 | CN |
| 49 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | Equity | 0.06% | $45K | 13,600 | CN |
| 50 | Shanghai Pharmaceuticals Holding Co., Ltd. | Equity | 0.04% | $25K | 11,200 | CN |
| 51 | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Equity | 0.04% | $25K | 5,400 | CN |
| 52 | BROWN BROTHERS HARRIMAN & CO. | Cash | 0.00% | $24 | 1 | HK |
| 53 | BROWN BROTHERS HARRIMAN & CO. | Cash | 0.00% | $14 | 1 | HK |
| 54 | BROWN BROTHERS HARRIMAN & CO. | Cash | 0.00% | $10 | 1 | HK |
| 55 | BROWN BROTHERS HARRIMAN & CO. | Cash | 0.00% | $8 | 1 | HK |
| 56 | BROWN BROTHERS HARRIMAN & CO. | Cash | 0.00% | $7 | 1 | HK |
| 57 | BROWN BROTHERS HARRIMAN & CO. | Cash | 0.00% | $3 | 1 | HK |
| 58 | BROWN BROTHERS HARRIMAN & CO. | Cash | 0.00% | $3 | 1 | HK |
| 59 | BROWN BROTHERS HARRIMAN & CO. | Cash | 0.00% | $2 | 1 | HK |
| 60 | N/A | Equity | 0.00% | $0 | 103,989 | US |
| 61 | BROWN BROTHERS HARRIMAN & CO. | Cash | -0.00% | −$15 | 1 | US |
| 62 | BROWN BROTHERS HARRIMAN & CO. | Cash | -0.00% | −$57 | 1 | US |
| 63 | BROWN BROTHERS HARRIMAN & CO. | Cash | -0.00% | −$92 | 1 | US |
Find which other funds hold a stock by opening it and choosing "ETFs holding".
Position changes between reports
| Action | Holding | Weight before | Weight after | Shares vs flows | Between reports |
|---|---|---|---|---|---|
| Decrease | Akeso Inc | 5.74% | 3.72% | −11.4% | Mar 31, 2026 → Jun 30, 2026 SEC |
| New position | Sichuan Biokin Pharmaceutical Co Ltd | — | 1.97% | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD. | 0.09% | 1.73% | +2255.8% | Mar 31, 2026 → Jun 30, 2026 SEC |
| New position | RemeGen Co Ltd | — | 1.26% | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 0.07% | 1.24% | +1945.7% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | Sichuan Kelun Pharmaceutical Co., Ltd. | 1.21% | 0.07% | −95.4% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | Shanghai Pharmaceuticals Holding Co., Ltd. | 1.04% | 0.04% | −96.5% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Exit | JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD. | 0.79% | — | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED | 3.59% | 2.85% | −12.0% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Exit | Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited | 0.72% | — | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Exit | SHANDONG WEIGAO GROUP MEDICAL POLYMER CO.,LTD | 0.64% | — | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | 1.56% | 1.85% | +15.6% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | WuXi AppTec Co., Ltd. | 3.12% | 3.35% | −24.1% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | WuXi AppTec Co., Ltd. | 5.68% | 5.79% | −27.1% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | Shanghai RAAS Blood Products Co., Ltd. | 0.87% | 0.79% | +10.3% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | CSPC PHARMACEUTICAL GROUP LIMITED | 3.61% | 3.68% | +23.1% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | HUADONG MEDICINE CO., LTD | 1.41% | 1.36% | +10.5% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. | 0.78% | 0.74% | +11.4% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. | 1.05% | 1.03% | +10.2% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | Jiangsu Hengrui Pharmaceuticals Co.,Ltd | 8.25% | 4.58% | −43.2% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | WuXi AppTec Co., Ltd. | 3.23% | 5.68% | +54.4% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD. | 2.08% | 0.09% | −95.3% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Increase | WuXi AppTec Co., Ltd. | 1.61% | 3.12% | +57.2% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Exit | Sichuan Biokin Pharmaceutical Co Ltd | 1.26% | — | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 1.15% | 0.07% | −94.7% | Dec 31, 2025 → Mar 31, 2026 SEC |
| New position | Hebei Changshan Biochemical Pharmaceutical Co Ltd | — | 0.76% | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | CSPC PHARMACEUTICAL GROUP LIMITED | 4.35% | 3.61% | −25.8% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Exit | Beijing Tiantan Biological Products Corporation Limited | 0.70% | — | — | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | WUXI BIOLOGICS (CAYMAN) INC. | 7.03% | 6.63% | −13.2% | Dec 31, 2025 → Mar 31, 2026 SEC |
| Decrease | CSPC Innovation Pharmaceutical Co Ltd | 1.05% | 0.73% | −24.9% | Dec 31, 2025 → Mar 31, 2026 SEC |
Share-count changes are measured after removing what creations and redemptions explain.
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.